Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven…

Overview of attention for article published in OncoTargets and therapy, June 2016

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 1,051 followers.

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of… https://t.co/mIV1zf5po1 #breastcancer

Reply Repost Favourite

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of… https://t.co/UE3NQlr8Qq #breastcancer

Reply Repost Favourite